1. Warden BA, Willman AM, Williams CD. Antithrombotics for secondary prevention of noncardioembolic ischaemic stroke.
Nat Rev Neurol 2012;8:223-235.
2. Kral M, Herzig R, Sanak D, Skoloudik D, Vlachova I, Bartkova A, et al. Oral antiplatelet therapy in stroke prevention. Minireview.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2010;154:203-210.
3. Alexandrov AV, Alagona P. Stroke and atherothrombosis: an update on the role of antiplatelet therapy.
Int J Stroke 2008;3:175-181.
4. Siller-Matula JM, Trenk D, Schrör K, Gawaz M, Kristensen SD, Storey RF, et al. Response variability to P2Y12 receptor inhibitors: expectations and reality.
JACC Cardiovasc Interv 2013;6:1111-1128.
5. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.
Pharmacol Ther 2013;138:103-141.
6. Alvarez-Sabin J, Quintana M, Santamarina E, Maisterra O. Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up.
Cerebrovasc Dis 2014;37:181-187.
7. Culebras A, Rotta-Escalante R, Vila J, Domínguez R, Abiusi G, Famulari A, et al. Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study.
Neurology 2004;62:1073-1080.
8. Han SW, Kim YJ, Ahn SH, Seo WK, Yu S, Oh SH, et al. Protocol for the comparison of triflusal and clopidogrel in secondary prevention of stroke based on cytochrome P450 2C19 genotyping (MASETRO study): a multicenter, randomized, open-label, parallel-group trial.
Int J Stroke 2016;11:485-491.
9. Mao L, Jian C, Changzhi L, Dan H, Suihua H, Wenyi T, et al. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.
Arch Cardiovasc Dis 2013;106:517-527.
10. Matias-Guiu J, Ferro JM, Alvarez-Sabín J, Torres F, Jiménez MD, Lago A, et al. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP study: a randomized, double-blind, multicenter trial.
Stroke 2003;34:840-848.
11. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
N Engl J Med 2008;359:1238-1251.
12. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel.
N Engl J Med 2009;360:354-362.
13. Lee JB, Lee KA, Lee KY. Cytochrome P450 2C19 polymorphism is associated with reduced clopidogrel response in cerebrovascular disease.
Yonsei Med J 2011;52:734-738.
14. Pan Y, Chen W, Xu Y, Yi X, Han Y, Yang Q, et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis.
Circulation 2017;135:21-33.
15. McDonough CW, McClure LA, Mitchell BD, Gong Y, Horenstein RB, Lewis JP, et al. CYP2C19 metabolizer status and clopidogrel efficacy in the secondary prevention of small subcortical strokes (SPS3) study.
J Am Heart Assoc 2015;4:e001652.
16. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
N Engl J Med 2013;369:11-19.
17. Wang Y, Zhao X, Lin J, Li H, Johnston SC, Lin Y, et al. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack.
JAMA 2016;316:70-78.
18. Hong KS, Lee SH, Kim EG, Cho KH, Chang DI, Rha JH, et al. Recurrent ischemic lesions after acute atherothrombotic stroke: clopidogrel plus aspirin versus aspirin alone.
Stroke 2016;47:2323-2330.
19. SPS3 Investigators, Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke.
N Engl J Med 2012;367:817-825.
20. Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.
BMJ 2011;343:d4588.
21. Paré G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.
N Engl J Med 2010;363:1704-1714.
22. Doll JA, Neely ML, Roe MT, Armstrong PW, White HD, Prabhakaran D, et al. Impact of CYP2C19 metabolizer status on patients with acs treated with prasugrel versus clopidogrel.
J Am Coll Cardiol 2016;67:936-947.
23. Jochmann N, Stangl K, Garbe E, Baumann G, Stangl V. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases.
Eur Heart J 2005;26:1585-1595.
24. Zaccardi F, Pitocco D, Willeit P, Laukkanen JA. Efficacy and safety of P2Y12 inhibitors according to diabetes, age, gender, body mass index and body weight: systematic review and meta-analyses of randomized clinical trials.
Atherosclerosis 2015;240:439-445.
25. Norrving B. Evolving concept of small vessel disease through advanced brain imaging.
J Stroke 2015;17:94-100.
26. Chan A, Pirmohamed M, Comabella M. Pharmacogenomics in neurology: current state and future steps.
Ann Neurol 2011;70:684-697.
27. Falcone GJ, Malik R, Dichgans M, Rosand J. Current concepts and clinical applications of stroke genetics.
Lancet Neurol 2014;13:405-418.